Astellas announces first clinical data from phase I study of gilteritinib
Astellas announced the first reported data of the investigational agent gilteritinib from the ongoing, open-label, dose escalation/expansion Phase 1 study (NCT02236013) in newly diagnosed patients with AML. The primary objective of the study is to assess the safety/tolerability profile. December 11, 2017